Biotech Values

[biopearl]

It was a very unfortunate journey for gtcb under its previous leadership. Among other disappointments, the guidance they provided for 2010 seems a bit inaccurate e.g. human studies for factor VIIa to be presented to FDA (they have two more weeks, resolution of dispute with LEO in first half of the year, they have two more weeks.) Maybe the new management can restore some accuracy and trust for the few minority shareholders that remain. Any thoughts about the CD 20 patents in Europe and how the goats might be affected? Also, it would seem the company, at least what's left of it could be acquired at any time by LFB, yet they have allowed some "independence" (of course they are totally dependent on LFB) but leave it as is for now, is it so the losses don't accrue to LBF directly or is it to encourage continued entrepreneurship against continuing high odds? Regards, bp